Biopharmaceutical Company Expands Clinical Trials On Texas A&M-Developed Angelman Syndrome Treatment
The disorder leads to developmental delay, speech impairment, movement or balance disorders, and seizures.
United States United Kingdom Scott Dindot Janie Hurley Carlb King Foundation For Angelman Syndrome Therapeutics
Source: tamu.edu